Adam Asch to Maximum Tolerated Dose
This is a "connection" page, showing publications Adam Asch has written about Maximum Tolerated Dose.
Connection Strength
0.051
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030.
Score: 0.051